Summary of SLRC Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Investment Income (NII): $0.33 per share, consistent with the previous quarter.

Net Income: $0.15 per share.

Net Asset Value (NAV): $18.00 per share, down from $18.16 in Q1 2026, primarily due to markdowns in two loans placed on non-accrual.

Comprehensive Portfolio: $3.2 billion, with $471 million in new investments and $431 million in repayments during the quarter.

Debt: $1.16 billion outstanding with a net debt-to-equity ratio of 1.16x, within the target range of 0.9x to 1.25x.

Gross Investment Income: $48.8 million, slightly down from $49.3 million in the prior quarter.

Quarterly Distribution: Declared at $0.31 per share, payable on September 25, 2026.

2Strategic Updates and Business Highlights

SLRC is focusing on specialty finance strategies, which accounted for nearly all originations in Q2.

The company has a strong liquidity profile with over $900 million available for deployment.

Increased activity in asset-based lending (ABL) with a focus on healthcare, where they have over 30 years of experience.

The firm is actively hiring and expanding its ABL and life sciences teams to enhance origination capabilities.

Formation of an AI committee to assess risks and opportunities related to AI in investment strategies.

3Forward Guidance and Outlook

SLRC expects continued strong originations in specialty finance, with a similar trend anticipated for Q3.

The company is positioned to take advantage of market dislocations, particularly in the healthcare sector.

Anticipates growth in net investment income over the next year through strategic initiatives and portfolio expansion.

4Bad News, Challenges, or Points of Concern

The decline in NAV was attributed to two loans placed on non-accrual, raising concerns about potential systemic issues, although management emphasized these are isolated cases.

The company faces challenges in the cash flow lending market due to increased competition and a lack of new transactions among private equity firms.

Concerns regarding the upcoming software maturity wall, with a significant portion of private debt exposure in the software sector potentially facing refinancing challenges.

5Notable Q&A Insights

Management indicated a willingness to increase leverage towards the higher end of their target range, reflecting confidence in their portfolio.

There is optimism regarding the life sciences sector due to increased M&A activity and FDA approvals, which could enhance investment opportunities.

The firm is seeing more opportunities from regional banks as they retreat from certain lending markets, particularly in ABL.

AI is viewed as a tool to enhance efficiency rather than a competitive threat, with ongoing efforts to integrate AI into their operations for better collateral management. Overall, SLRC's Q2 2026 performance reflects a stable financial position with a strategic focus on specialty finance and asset-based lending, while navigating challenges in the broader lending environment.